国金证券给予安科生物买入评级，母公司收入维持增长，创新布局加速推进

Group 1 - The core viewpoint of the report is that Anke Bio (300009.SZ) is rated as a buy due to its continuous development in main business and overall stable performance of the parent company [2] - The company is actively expanding new business areas to create growth points for its performance [2] - Anke Bio is focusing on cutting-edge technologies, with accelerated innovation and research and development efforts [2]